In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Biocryst Pharmaceuticals Inc’s stock clocked out at $7.25, down -3.33% from its previous closing price of $7.50. In other words, the price has decreased by -$3.33 from its previous closing price. On the day, 2.25 million shares were traded. BCRX stock price reached its highest trading level at $7.49 during the session, while it also had its lowest trading level at $7.22.
Ratios:
To gain a deeper understanding of BCRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.58 and its Current Ratio is at 2.63.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wedbush on February 25, 2025, initiated with a Outperform rating and assigned the stock a target price of $15.
RBC Capital Mkts Upgraded its Sector Perform to Outperform on September 18, 2023, whereas the target price for the stock was revised from $9 to $10.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 13 ’24 when Hutson Nancy J sold 7,000 shares for $7.54 per share. The transaction valued at 52,780 led to the insider holds 86,638 shares of the business.
Hutson Nancy J bought 7,000 shares of BCRX for $52,584 on Dec 13 ’24. On Jun 24 ’24, another insider, McKee Amy E, who serves as the Director of the company, sold 8,600 shares for $6.32 each. As a result, the insider received 54,352 and left with 27,831 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1514960000 and an Enterprise Value of 2035528192. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.36. Its current Enterprise Value per Revenue stands at 4.516 whereas that against EBITDA is 1174.569.
Stock Price History:
The Beta on a monthly basis for BCRX is 1.75, which has changed by 0.53276956 over the last 52 weeks, in comparison to a change of 0.08089435 over the same period for the S&P500. Over the past 52 weeks, BCRX has reached a high of $9.50, while it has fallen to a 52-week low of $4.03. The 50-Day Moving Average of the stock is -10.95%, while the 200-Day Moving Average is calculated to be -5.33%.
Shares Statistics:
It appears that BCRX traded 3.25M shares on average per day over the past three months and 2785480 shares per day over the past ten days. A total of 208.54M shares are outstanding, with a floating share count of 197.24M. Insiders hold about 5.61% of the company’s shares, while institutions hold 78.44% stake in the company. Shares short for BCRX as of 1741910400 were 19774241 with a Short Ratio of 6.08, compared to 1739491200 on 16675736. Therefore, it implies a Short% of Shares Outstanding of 19774241 and a Short% of Float of 9.54.
